GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Stem Cell Therapy Cause Cancer?

Yes. Cancer is a possible complication of some stem-cell-based treatments, but the risk depends on the cells and the treatment around them. Not every post-treatment growth is cancer: a tumor may be benign or malignant. What is cancer

Hematopoietic stem cell transplantation (HSCT), used for blood cancers and certain blood disorders, carries a risk of second cancers. A 2018 review reported solid tumors in up to 15% of patients 15 years after myeloablative conditioning, the intensive treatment given before transplant. That is not a risk estimate for a knee injection. Donor-cell leukemia is a separate, rare complication. Stem cell transplant S11864 018 0528 y J.bbmt.2010.10.010

Can Stem Cell Therapy Cause Cancer?

Published reports also document donor-derived growths after fetal neural cell injections and clinic infusions described as containing several cell types. These show that serious tumors can occur, but do not establish a cancer rate for other products. Journal.pmed.1000029 NEJMc1600188

For mesenchymal stromal cells (MSCs), the studies discussed here do not establish an increased cancer risk. The 2012 intravascular safety review did not detect an association with malignancy. A knee study followed only 11 patients for five years; a 2025 knee meta-analysis assessed general adverse events, not long-term cancer incidence. None proves zero lifetime risk. Journal.pone.0047559 Szac024 S13287 025 04252 2

The short answer on cancer risk

Treatment Cancer or tumor evidence Important limit
HSCT for selected blood cancers or blood disorders Second cancers are recognized; donor-cell leukemia is rare. Stem cell transplant S11864 018 0528 y J.bbmt.2010.10.010 Conditioning, prior treatment, immune complications and patient factors contribute; this is not the same as a clinic MSC injection.
Fetal neural cells or poorly characterized clinic mixtures Donor-derived brain and spinal growths have been reported. Journal.pmed.1000029 NEJMc1600188 Case reports show possible harm, not how often it occurs or that every growth is malignant.
Products derived from embryonic or induced pluripotent stem cells Residual undifferentiated cells are a tumorigenicity concern. Nm.3267 Risk depends on differentiation, purification, testing and the specific product; animal findings do not supply a human rate.
MSCs studied by intravascular or knee-joint injection No malignancy association detected in the 2012 review; limited longer-term knee safety data. Journal.pone.0047559 Szac024 These findings cannot validate unrelated spine, anti-aging or wellness services.
Unapproved regenerative products marketed without adequate oversight The FDA reports tumor formation, infections and blindness. Important patient and consumer information about regenerative medicine therapies There is no reliable denominator for a product-specific cancer rate.

“No signal” does not mean “no risk.” The FDA warns that unapproved regenerative products can form tumors or grow into unintended tissue. Its reports are safety warnings, not a controlled comparison between treatments. Important patient and consumer information about regenerative medicine therapies

What counts as cancer

Cancer involves uncontrolled cell growth with the ability to invade nearby tissue or spread elsewhere. Some cancers, such as leukemia, do not form a solid tumor. A benign tumor does not invade or spread, but can still cause serious harm in the brain or spinal canal. What is cancer

When growths followed treatment

A donor-derived brain tumor

A boy with ataxia telangiectasia received human fetal neural stem cells in 2001, 2002, and 2004 at a Moscow hospital. The cells were injected into his brain and spinal fluid. He was 9 the first time. At 13, four years after the first injection, he developed recurrent headaches. MRI showed lesions in his brain and spinal cord. Surgeons removed a spinal lesion when he was 14. It was a glioneuronal tumor. Journal.pmed.1000029

Molecular testing showed the tumor cells were not his own. X/Y chromosome analysis, HLA (tissue-type) typing, and microsatellite markers traced the mass to at least two donors. It grew slowly, with a Ki-67 (MIB-1) index of about 1%, and showed no malignancy, necrosis, or abnormal vessels under the microscope. The authors noted that patients with ataxia telangiectasia have immune abnormalities, which may have allowed the donor cells to persist. Journal.pmed.1000029

This single case has no denominator: it cannot tell another patient how likely a tumor is.

A spinal neoplasm after clinic infusions

In 2016, doctors at Brigham and Women’s Hospital described a 66-year-old man. He had received infusions into his spinal fluid at commercial stem-cell clinics in China, Argentina, and Mexico. The clinics described the infusions as mesenchymal, embryonic, and fetal neural stem cells. He was not taking immunosuppressive drugs. NEJMc1600188

He developed worsening back pain, paraplegia and urinary incontinence. Imaging and biopsy found a highly proliferative spinal neoplasm with glial differentiation. DNA fingerprinting showed predominantly nonhost cells. The lesion had features overlapping malignant glioma, but could not be assigned to a recognized human tumor category; sequencing of 309 cancer-associated genes detected no cancer-associated abnormality. That negative panel did not prove the lesion was benign. Radiation reduced the lesion and improved symptoms. NEJMc1600188

Because he received treatments at several clinics, the report cannot identify which infusion or advertised cell type produced the growth.

A kidney mass after direct injection

A report published in 2010 described a woman with lupus nephritis who received direct kidney injections of autologous peripheral-blood cells at a private clinic in 2006. She later developed masses at injection sites and blood in her urine. After removal of the kidney, pathology showed angiomyeloproliferative lesions: abnormal blood-vessel and marrow-element growth. The authors considered them stem-cell-derived or stem-cell-induced, but their neoplastic potential was unknown. ASN.2009111156

The lesions were not diagnosed as conventional cancer. That is not the same as proving that every autologous injection is safe.

Why pluripotent cells can form tumors

Embryonic and induced pluripotent stem cells can give rise to many specialized cell types. Residual undifferentiated cells can form teratomas in animal models. A teratoma may contain several tissue types; it is not automatically malignant. This is a manufacturing safety concern, not a measured human cancer rate. Nm.3267

Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) lists guidance on residual undifferentiated cells, transformed cells, tumorigenicity and genomic stability. The relevant tests depend on the starting cells and final product. A sterility result alone cannot answer a tumorigenicity question. 0003

Why donor cells can turn cancerous

Donor-cell leukemia after allogeneic HSCT is leukemia arising in donor-derived blood-forming cells, rather than a return of the recipient’s original leukemia. It is rare and requires molecular testing to distinguish it from relapse. Its mechanisms are complex; donor origin alone does not identify why the malignancy developed. J.bbmt.2010.10.010

What culture and processing change

Growing cells in a laboratory can select for genetic changes, but a detected change is not automatically malignant transformation.

In one study, researchers followed nine human umbilical cord MSC clones through long-term culture. Seven of the nine had at least one copy-number variation by passage 30 compared with passage 3. One clone had an extra copy of chromosome 10. None of the clones formed tumors when injected into immunodeficient mice. The authors recommended genomic monitoring before clinical use. Cddis.2013.480

A separate experiment using cultured mouse bone-marrow MSCs produced malignant sarcomas after injection into mouse heart or hindlimb tissue. These were mouse cells in mouse disease models, not human treatment outcomes. CIRCRESAHA.110.239848

The standard transplant risk is different

HSCT restores blood formation after chemotherapy or radiation for selected diseases, including leukemia, lymphoma and multiple myeloma. Donor immune cells can also attack residual leukemia through a graft-versus-tumor effect. It is an established treatment in selected patients, not equivalent to a privately marketed MSC infusion. Stem cell transplant

In the 2018 review, solid tumors occurred in up to 15% of patients 15 years after myeloablative conditioning, with no plateau in incidence. The review attributed 5–10% of late deaths to solid malignancies; that is a share of late deaths, not a 5–10% risk for every recipient. Total body irradiation and chronic graft-versus-host disease were major risk factors. Therapy-related myeloid cancers were more common after autologous transplant and may relate mainly to earlier treatment. S11864 018 0528 y

An autologous graft uses the patient’s own cells and can carry a small risk of transplanting cancer cells already present. This is different from healthy transplanted cells becoming malignant. Stem cell transplant

Transplant survivors need long-term cancer surveillance tailored by their transplant team. The review recommends lifelong screening. These risks should be weighed against the disease being treated, not used alone to reject a potentially life-saving transplant. S11864 018 0528 y

Adult stem cells and cancer

The 2012 SafeCell review included 36 prospective intravascular MSC studies with 1,012 participants across several conditions. Eight were randomized trials, with 321 participants. The randomized-trial analysis did not detect an association with malignancy, but did find more transient fever. Products, diseases and follow-up varied, and the authors called for better adverse-event reporting. This is older, route-specific evidence, not a survey of every MSC treatment available today. Journal.pone.0047559

A Korean single-arm knee osteoarthritis study followed 11 patients for five years after one intra-articular injection of 100 million autologous adipose-derived MSCs. It reported no treatment-related adverse events, but had no control group and was far too small to exclude a rare cancer. Szac024

A 2025 meta-analysis included 8 randomized trials and 502 patients with knee osteoarthritis. Pain and function were assessed at 6 and 12 months, and pooled general adverse events did not differ significantly between MSC and control groups. That result does not establish a long-term cancer rate or validate a different cell source, dose or route. S13287 025 04252 2

A review of largely preclinical research describes both tumor-promoting and tumor-inhibiting MSC effects, depending on the model. Those findings do not establish that MSC injections cause cancer in people or safely treat an existing cancer. Cas.13334

If you have a current or previous cancer, ask your oncologist to assess the proposed product rather than applying knee-study results to your situation. The studies above cannot provide a personalized recurrence estimate.

What if a clinic offers stem cells for cancer?

HSCT for a blood cancer should not be confused with a clinic selling MSC injections as a cancer cure. The FDA warns about harm from unapproved regenerative products. Do not postpone established cancer care on the basis of a clinic testimonial or an animal experiment. Important patient and consumer information about regenerative medicine therapies

Japan’s filing is not an approval

In Japan, provision of regenerative medicine under the Act on the Safety of Regenerative Medicine (ASRM) involves a risk-classified provision plan and certified committee review. The MHLW provides plan-submission and reporting information. Ask for the plan applicable to the actual procedure, not a certificate for a different service. Plan

An ASRM filing is not marketing approval and does not establish clinical efficacy or zero cancer risk. Product marketing approval is a separate route under Japan’s Pharmaceuticals and Medical Devices Act, with PMDA review. Japan also has conditional, time-limited approval for certain regenerative medical products, with further efficacy evaluation. 0003

If a provider says “approved in Japan,” ask for the exact product, indication and authorization route. For a marketed product, check the authorization and product information; for an ASRM service, check the provision plan and evidence for that procedure.

How to judge a clinic’s cancer risk

Use these questions to identify evidence gaps before you consent. Even complete documents may not allow a numerical estimate of a rare, late cancer.

Question Why it matters A solid answer looks like
What exactly are you giving me? “Stem cells” can mean many products Cell type, tissue source, donor or autologous, passage number, cell count
How was the product tested? Tumorigenicity and contamination are manufacturing issues Product-specific sterility, viability and genetic-stability results; explain whether residual pluripotent-cell and tumorigenicity tests apply
What human evidence exists for my condition? Animal and lab data do not prove benefit Trial phase, sample size, endpoint, follow-up, adverse events, publication
What is the regulatory route? A safety filing is not efficacy approval ASRM plan details, named product authorization, or trial authorization and registration; these are not interchangeable
What is the dose and route? Route changes risk Cells per dose, number of doses, intravenous, intra-articular, intrathecal, or other
What is the long-term follow-up? Tumors can appear years later A clinician-led schedule, duration, symptom-reporting contact, and responsibility for follow-up; imaging when clinically indicated
What happens if a mass is found? Early diagnosis matters Biopsy pathway, specialist referral, records transfer
What are the alternatives? Proven care may be delayed A clear comparison with standard treatment, without pressure

Red flags:

  • “Stem cells cannot cause cancer.” That is false as a blanket statement.
  • “Autologous means there is no risk.” Autologous removes donor-derived risk. It does not remove processing, route, or host risk.
  • “You do not need follow-up.” Any proliferative cell treatment needs a follow-up plan.
  • “We are approved in Japan.” Ask for the exact route and product. Do not accept the sentence alone.
  • “Our MSC injection cures cancer.” Ask your oncologist whether there is credible human evidence for that exact use.
  • “Stop your other treatment first.” Do not stop proven treatment without your treating clinician.

ISSCR guidance calls for rigorous oversight and evidence-based clinical translation. A trial registration establishes that a study was registered, not that it succeeded or that the intervention is authorized for routine use. Guidelines

For U.S. authorization claims, compare the exact product with the FDA’s approved cellular and gene therapy list and its product-specific labeling. Approval for one indication does not authorize a knee, spine or wellness use. The list does not rank products by cancer risk. Approved cellular and gene therapy products

Holding a quote or a treatment plan and unsure what it means for you?

Share the documents you have received, and get help organizing the questions worth asking before you pay.

Ask About Your Plan

Watching for tumors after treatment

Tell your primary care doctor or oncologist what you received, where, and when. Bring the clinic’s records: cell type, dose, route, number of treatments, and any lot or release information.

Seek medical assessment for a new mass, persistent unexplained pain, blood in the urine or neurological changes after treatment. New leg weakness or loss of bladder control warrants urgent assessment, not waiting for a routine clinic follow-up. Tell the clinician if cells were injected into spinal fluid or directly into an organ. The published spinal case illustrates why that history matters. NEJMc1600188

Report suspected serious adverse effects to the treating clinician and relevant regulator. In the United States, the FDA specifically encourages reporting through MedWatch. A report raises a safety concern; it does not itself establish causation. Important patient and consumer information about regenerative medicine therapies

Comparing an offer with a study

If a clinic cites the five-year knee study to support repeated intravenous “anti-aging” infusions, compare the actual protocol: the paper followed 11 knee osteoarthritis patients after one joint injection of their own adipose-derived MSCs. Szac024 The disease, route and treatment schedule do not match that offer. The study cannot supply its long-term cancer rate. Ask the clinic to identify evidence for its exact product and protocol instead of accepting the phrase “the same stem cells.”

Bottom line

Stem-cell-based treatment can be associated with cancer, and injected cells have caused serious growths. There is no single risk percentage. The review’s “up to 15% at 15 years” concerns solid tumors after myeloablative HSCT, not ordinary cell injections or the chance that an injected cell becomes cancerous. S11864 018 0528 y

For the MSC knee study, five-year safety data cover just 11 patients. Szac024 That is useful follow-up, not proof of zero risk. Ask for product-specific evidence and a follow-up plan; involve your transplant team or oncologist when cancer is part of your medical history.

This is general medical information based on the sources cited, checked in October 2026. It cannot estimate your personal cancer risk or replace assessment by a qualified clinician who knows your diagnosis, previous cancer treatment and the proposed cell product.